CXCR2 chemokine receptor - a master regulator in cancer and physiology

Trends Mol Med. 2024 Jan;30(1):37-55. doi: 10.1016/j.molmed.2023.09.003.

Gwendal Lazennec ¹, Krishna Rajarathnam ², Ann Richmond ³

Affiliations

1 Centre National de la Recherche Scientifique (CNRS), Sys2Diag-ALCEDIAG, Cap Delta, Montpellier, France; CNRS Groupement de Recherche (GDR) 3697 'Microenvironment of Tumor Niches', Micronit, France. Electronic address: [email protected].
2 Department of Biochemistry and Molecular Biology, Department of Microbiology and Immunology, Sealy Center for Structural Biology and Molecular Biophysics, University of Texas Medical Branch, Galveston, TX, USA.
3 Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, TN, USA; Vanderbilt University School of Medicine, Department of Pharmacology, Nashville, TN, USA; Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.

PMID: 37872025 DOI: 10.1016/j.molmed.2023.09.003

Abstract

Recent findings have modified our understanding of the roles of Chemokine Receptor CXCR2 and its ligands in Cancer, inflammation, and immunity. Studies in CXCR2 tissue-specific knockout mice show that this receptor is involved in, among Other things, Cancer, central nervous system (CNS) function, metabolism, reproduction, COVID-19, and the response to circadian cycles. Moreover, CXCR2 involvement in neutrophil function has been revisited not only in physiology but also for its major contribution to cancers. The recent unfolding of the role of CXCR2 in numerous cancers has led to extensive evaluation of multiple CXCR2 antagonists in preclinical and clinical studies. In this review we discuss the potential of targeting CXCR2 for Cancer treatment.

Keywords

CXCR2; cancer; chemokine receptor; glycosaminoglycan; inflammation; neutrophil.

Name
Email *

	Sorry, but the email address you supplied was invalid.